Wed, Oct 1, 2014, 11:15 AM EDT - U.S. Markets close in 4 hrs 45 mins

Recent

% | $
Quotes you view appear here for quick access.

Momenta Pharmaceuticals Inc. Message Board

  • scaffp scaffp Sep 14, 2011 9:06 AM Flag

    What is wrong with MNTA?

    I have been holding and adding to my MNTA position since 2007, but I am frankly running out of patience. Everyone bashes investorgold and others who post anything negative, and maybe they are motivated by short positions - who knows. But there is no doubting they make some valid points.
    Why, oh why, is this stock trading at less than $17?? When it was making zero money it traded around $14 on the mere hopes that M-enox would get approved! Now we have M-enox and have been printing money for more than a year and we only move up to $17??? Why aren't the insiders jumping all over this at these prices??? Since M-enox approval I keep adding whenever it is below $16, but I wonder - are the insiders morons or am I the idiot?
    I'm beginning to think that management thought that once they got M-enox they would get bought out for a nice premium, take their payday and go home, because they don't appear to be doing much else. FOB program? Anything new in the pipeline? Any movement on the existing pipeline? The picture on all of those things hasn't changed much since 2007! Nothing appears to be going on except Copaxone. It is clear now that MNTA is not going to rise to $40+ where it belongs on the merits of the m-enox program alone. Some new catalyst will be needed and copaxone is the only thing on the visible horizon. God help us if that doesn't go well.
    I have been dismissing these negatives for a long time, but I can't anymore. There is something wrong here. Someone give me a reason to keep believing!

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
MNTA
11.39+0.05(+0.44%)11:14 AMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.